Although PD-L1 has been correlated with poor prognosis in BC, several clinical trials have reported the positive association of PD-L1 expression with higher response rates to anti-PD-1/PD-L1 antibody therapy (145, 146). The gene discussed is CD274; the disease is breast cancer.